Filing Flows › Syndax Pharmaceuticals (SNDX) › Q1 2025
Syndax Pharmaceuticals (SNDX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Syndax Pharmaceuticals (SNDX) reported revenue of $20.0M for the first quarter 2025 (Q1 2025) and +161% from the quarter before. Operating margin was -417.9%, net loss $84.8M (423.3% of revenue).
Syndax Pharmaceuticals, Q1 2025: revenue $20.0M, operating margin -417.9%, net loss $84.8M, operating cash flow −$95.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | +161% | — |
| Operating profit | −$83.8M | — | — |
| Net earnings | −$84.8M | — | — |
| Operating cash flow | −$95.2M | — | — |
What changed
Revenue was $20.0M in Q1 2025, up 161% from the previous quarter.
Operating costs exceeded revenue by $83.8M, an operating margin of -417.9%. The quarter ended with a net loss of $84.8M, narrower than the previous quarter's $94.2M loss.
Operating cash flow was −$95.2M. Non-cash charges added back $10.4M of share-based compensation. Working capital and other items used $20.7M.
Questions
What was Syndax Pharmaceuticals' revenue in the first quarter 2025?
Syndax Pharmaceuticals (SNDX) reported revenue of $20.0M for the first quarter 2025 (Q1 2025) and +161% from the quarter before.
Was Syndax Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $83.8M (-417.9% of revenue) and net loss $84.8M.